BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16212714)

  • 1. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Hsiao CF; Wang JL; Chen MY; Hsieh SM; Sheng WH; Chang SC
    Int J STD AIDS; 2005 Oct; 16(10):673-6. PubMed ID: 16212714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
    Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
    Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.
    Levin MJ; Anderson JP; Seage GR; Williams PL;
    J Acquir Immune Defic Syndr; 2009 Feb; 50(2):182-91. PubMed ID: 19131890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era.
    Moanna A; Rimland D
    Clin Infect Dis; 2013 Jul; 57(1):122-5. PubMed ID: 23487391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era.
    Gebo KA; Kalyani R; Moore RD; Polydefkis MJ
    J Acquir Immune Defic Syndr; 2005 Oct; 40(2):169-74. PubMed ID: 16186734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of co-infection.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Int J STD AIDS; 2005 Jan; 16(1):42-8. PubMed ID: 15705272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
    Gona P; Van Dyke RB; Williams PL; Dankner WM; Chernoff MC; Nachman SA; Seage GR
    JAMA; 2006 Jul; 296(3):292-300. PubMed ID: 16849662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.
    Tangsinmankong N; Kamchaisatian W; Lujan-Zilbermann J; Brown CL; Sleasman JW; Emmanuel PJ
    J Allergy Clin Immunol; 2004 Apr; 113(4):742-6. PubMed ID: 15100682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes zoster among persons living with HIV in the current antiretroviral therapy era.
    Blank LJ; Polydefkis MJ; Moore RD; Gebo KA
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):203-7. PubMed ID: 22766968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
    Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
    J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy.
    Weinberg A; Wiznia AA; LaFleur BJ; Shah S; Levin MJ
    J Infect Dis; 2004 Jul; 190(2):267-70. PubMed ID: 15216460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors.
    Dunić I; Djurković-Djaković O; Vesić S; Zerjav S; Jevtović D
    Int J STD AIDS; 2005 Jul; 16(7):475-8. PubMed ID: 16004625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
    Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D;
    J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.
    Yang CH; Huang YF; Hsiao CF; Yeh YL; Liou HR; Hung CC; Yang SY
    HIV Med; 2008 Aug; 9(7):535-43. PubMed ID: 18554309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study.
    Glesby MJ; Hoover DR; Tan T; Shi Q; Gao W; French AL; Maurer T; Young M; Dehovitz J; Ru J; Anastos K
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1604-9. PubMed ID: 15577417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006.
    Wood SM; Shah SS; Steenhoff AP; Rutstein RM
    Pediatrics; 2008 Jan; 121(1):e150-6. PubMed ID: 18086820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.